Orion Secures Orphan Drug Designation in US for Investigational Drug for Mesothelioma
Idag, 16:36
10:36 AM EDT, 04/20/2026 (MT Newswires) -- Orion (ORNAV.HE, ORNBV.HE) on Monday said its cancer treatment medication, ODM-212, secured an orphan drug designation from the US Food and Drug Administration.
The investigational drug being tested for the treatment of mesothelioma received the designation given to investigational therapies that treat rare diseases or affect fewer than 200,000 people.
The Finnish pharmaceutical company's ODM-212 is in the second phase of its clinical study, where it is being tested on patients whose illnesses have progressed after receiving standard treatments and have no other treatment options.
Orion Secures Orphan Drug Designation in US for Investigational Drug for Mesothelioma
Idag, 16:36
10:36 AM EDT, 04/20/2026 (MT Newswires) -- Orion (ORNAV.HE, ORNBV.HE) on Monday said its cancer treatment medication, ODM-212, secured an orphan drug designation from the US Food and Drug Administration.
The investigational drug being tested for the treatment of mesothelioma received the designation given to investigational therapies that treat rare diseases or affect fewer than 200,000 people.
The Finnish pharmaceutical company's ODM-212 is in the second phase of its clinical study, where it is being tested on patients whose illnesses have progressed after receiving standard treatments and have no other treatment options.
Banker
Analys
Banker
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
-160x160.jpg&w=3840&q=75)
